文章摘要
崔鑫铭,董宇曦,尚凤琴,刘秀盈,朱晶晶,刘静静,冯义超,王建勋.靶向人源BCMA的嵌合抗原受体T细胞构建及体外抗肿瘤活性研究[J].,2024,(1):18-24
靶向人源BCMA的嵌合抗原受体T细胞构建及体外抗肿瘤活性研究
Construction of Chimeric Antigen Receptor T Cells Targeting Human BCMA and its Antitumor Activity in Vitro
投稿时间:2023-07-10  修订日期:2023-07-31
DOI:10.13241/j.cnki.pmb.2024.01.004
中文关键词: B细胞成熟抗原  嵌合抗原受体  ScFv单链可变区  T细胞
英文关键词: B cell maturation antigen  Chimeric antigen receptor  ScFv single-chain variable region  T cell
基金项目:王建勋高层次人才科研启动经费项目(9011451310032)
作者单位E-mail
崔鑫铭 北京中医药大学生命科学学院 北京 102400 cuixinming0722@163.com 
董宇曦 北京中医药大学生命科学学院 北京 102400  
尚凤琴 深圳北京中医药大学研究院 广东 深圳 518118  
刘秀盈 北京中医药大学生命科学学院 北京 102400  
朱晶晶 北京中医药大学生命科学学院 北京 102400  
刘静静 北京中医药大学生命科学学院 北京 102400  
冯义超 北京中医药大学生命科学学院 北京 102400  
王建勋 北京中医药大学生命科学学院 北京 102400深圳北京中医药大学研究院 广东 深圳 518118  
摘要点击次数: 135
全文下载次数: 118
中文摘要:
      摘要 目的:通过对CAR结构的ScFv单链可变区进行改造,构建并筛选具有更强杀伤肿瘤细胞功能的新型靶向人源B细胞成熟抗原(BCMA)的嵌合抗原受体 (CAR)-T细胞。方法:构建靶向人源BCMA的CAR分子,用逆转录病毒载体包装成功后转导健康志愿者的T细胞,制备Anti-BCMA-CAR-T细胞。将Anti-BCMA-CAR-T细胞作为观察组,普通T细胞作为对照组,将其与RPMI-8226细胞共培养,采用CFSE染色的T细胞增殖实验观察两组体外增殖能力。采用荧光素酶化学发光实验检测两组细胞在不同效靶比(1:8、1:4、1:2、1:1、2:1、4:1)对RPMI-8226细胞的杀伤效率,采用流式细胞术检测两组细胞在不同效靶比(1:4、1:2、1:1、2:1、4:1)对RPMI-8226细胞的杀伤效率。结果:CFSE检测结果显示,与对照组比较,观察组FITC信号明显左移,表明T细胞增殖能力越强。流式细胞术检测结果显示,相同效靶比时,观察组对RPMI-8226细胞的杀伤效率均高于对照组(P均<0.05);荧光素酶化学发光实验结果显示,相同效靶比时,观察组对RPMI-8226细胞的杀伤效率均高于对照组(P均<0.05)。在效靶比为4:1时,CAR170-T(未经改造的传统的ScFv)细胞和CAR174-T(经改造的ScFv)细胞的杀伤效率分别达到了88.5±0.3 %和98.5±0.7 %。结论:通过对CAR结构的ScFv单链可变区进行改造后成功构建出的新型靶向BCMA的CAR-T细胞,它能保持较强的增殖活性且具有更强的杀伤肿瘤细胞的能力。
英文摘要:
      ABSTRACT Objective: To construct and screen the new type of chimeric antigen receptor CAR-T cell targeting human-derived B cell maturation antigen(BCMA), By modifying the ScFv single-chain variable region of the CAR structure, a novel chimeric antigen receptor (CAR)-T cell targeting human B-cell maturation antigen (BCMA) with a stronger ability to kill tumor cells was constructed and screened. Methods: We constructed a CAR molecule targeting BCMA human ScFv, and after successful packaging with retroviral vector,transducing T cells from healthy volunteers to prepare Anti-BCMA-CAR-T cells. Anti-BCMA-CAR-T cells were used as the observation group and normal T cells were used as the control group, they were co-cultured with RPMI-8226 cells, and the proliferation ability of the two groups in vitro was observed by the T cell proliferation experiment stained with CFSE. The killing efficiency of two groups of cells on RPMI-8226 cells at different effect-to-target ratios (1:8, 1:4, 1:2, 1:1, 2:1, 4:1) was detected by luciferase chemiluminescence assay. Flow cytometry was used to detect the killing efficiency of the two groups of cells on RPMI-8226 cells at different effect-to-target ratios (1:4, 1:2, 1:1, 2:1, 4:1). Results: CFSE detection results showed that compared with the control group, the FITC signal in the observation group shifted significantly to the left, indicating that the T cell proliferation ability was stronger. The results of flow cytometry showed that at the same effect target ratio, the killing efficiency of the observation group on RPMI-8226 cells was higher than that of the control group (both P<0.05); the results of luciferase chemiluminescence experiment showed that the same effect target ratio, the killing efficiency of RPMI-8226 cells in the observation group was higher than that in the control group (P<0.05). When the effect-to-target ratio was 4:1, the killing efficiencies of CAR170-T (unmodified conventional ScFv) cells and CAR174-T (modified ScFv) cells reached 88.5±0.3 % and 98.5±0.7%, respectively. Conclusion: We successfully constructed a novel type of BCMA-targeting CAR-T cells by modifying the ScFv single-chain variable region of the CAR structure, which can maintain strong proliferative activity and have a stronger ability to kill tumor cells.
查看全文   查看/发表评论  下载PDF阅读器
关闭